Intercept Pharmaceuticals inc (ICPT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ICPT Annual Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Intercept Pharmaceuticals inc finances operations and invests in assets.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent102.74
Security Deposit1.28
Cash & Short-term Investments103.00
Accounts receivable32.48
Other Current Assets219.62
Prepaid Expense And Other Assets Current27.33
Total Current Assets383.45
Equipment/Property/Plant Net0.82
Other Assets, Noncurrent8.90
Restricted Cash Current0.92
Total Assets393.16
Liabilities
Accounts Payable and Accrued Liabilities, Current LI89.49
Interest and Dividends Payable, Current AC1.35
Debt, Current LI0.00
Total Current Liabilities90.85
Long-term debt223.86
Total Long-term Debt223.86
Other liabilities, Noncurrent6.62
Total Liabilities321.32
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock2,256.68
Retained Earnings / Accumulated Deficit-2,177.68
Other Equity-7.20
Common Stockholder's Equity71.85
Total Stockholder's Equity71.85
Liabilities & Stockholder's Equity393.16
4 historic quarters locked

Sign in to unlock the full Intercept Pharmaceuticals inc balance sheet history.

About Intercept Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-23-017790

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.